SCHEMBL6813373

SCHEMBL6813373

CC(NC(=O)/C=C/c1cccc(C(F)(F)F)c1)c1cccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 1/20 0.53
HSP90AA1 P07900 1/20 0.53
MAPT P10636 1/20 0.53
PKM P14618 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HTT P42858 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
THRB P10828 1/20 0.52
MAOB P27338 2/20 0.49
ADRA2C P18825 2/20 0.48
SLC6A2 P23975 2/20 0.48
HTR2C P28335 2/20 0.48
SLC6A4 P31645 2/20 0.48
OPRM1 P35372 2/20 0.48
DRD3 P35462 2/20 0.48
CASR P41180 2/20 0.48
MLNR O43193 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1329587 1.00 KDM4E (0.54) KDM4EMEN1KMT2ALMNAHSP90AA1
SCHEMBL4732908 1.00 KDM4E (0.54) KDM4EMEN1KMT2ALMNAHSP90AA1
SCHEMBL4732912 1.00 KDM4E (0.54) KDM4EMEN1KMT2ALMNAHSP90AA1
SCHEMBL8468918 1.00 KDM4E (0.54) KDM4EMEN1KMT2ALMNAHSP90AA1
SCHEMBL1329590 1.00 KDM4E (0.54) KDM4EMEN1KMT2ALMNAHSP90AA1
SCHEMBL6752550 0.84 TDP1 (0.50) LMNAMAOBTDP1
SCHEMBL13855361 0.80 MEN1 (0.51) KDM4EMEN1KMT2ALMNAHSP90AA1
SCHEMBL1504899 0.80 MEN1 (0.48) KDM4EMEN1KMT2ALMNAHSP90AA1
Fumaric Acid SCHEMBL1504896 0.80 CASR (0.51) KDM4EMEN1KMT2ALMNAHSP90AA1
Fumaric Acid SCHEMBL1504902 0.80 CASR (0.51) KDM4EMEN1KMT2ALMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406211-B1 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF MEGAFINE PHARMA P LTD (IN) 2018-06-27 EP disclosed
EP-2170805-B1 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF AMGEN INC (US) 2016-03-16 EP disclosed
US-8183415-B2 Methods of synthesizing cinacalcet and salts thereof AMGEN, INC. (US) 2012-05-22 US disclosed
US-20110281954-A1 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF AMGEN INC. 2011-11-17 US disclosed
US-20090137837-A1 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF AMGEN INC. 2009-05-28 US disclosed
US-20090137837-A1 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF AMGEN INC. 2009-05-28 US disclosed
WO-2009002427-A2 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF AMGEN INC. (US) 2008-12-31 WO disclosed
WO-2008058235-A2 PROCESSES FOR THE PREPARATION OF CINACALCET DR. REDDY'S LABORATORIES, LTD. (IN) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137837-A1 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF ACE, SI, REN KDM4E 2601/4885MEN1 557/4885KMT2A 3343/4885
US-20110281954-A1 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF ACE, SI, REN KDM4E 2601/4885MEN1 557/4885KMT2A 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.